> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Collegium’s Pain Sales Fall 18% As ADHD Growth Leaves Earnings Behind
- URL: https://www.bullished.co/collegiums-pain-sales-fall-18-as-adhd-growth-leaves-earnings-behind-a3e0c664/
- Published: 2026-11-06T16:25:50.000Z
- Updated: 2026-11-06T16:25:50.000Z
- Description: Jornay PM sales grew 24%, but operating expenses rose faster and Collegium kept its annual forecasts unchanged.
- Author: Matteo Parrino
- Tags: Earnings, COLL, Industry: Healthcare

[Collegium Pharmaceutical](https://www.bullished.co/tag/coll/), which sells prescription ADHD and pain medicines, reported an [18% decline](https://www.sec.gov/Archives/edgar/data/0001267565/000162828026070585/coll-20261105.htm?ref=bullished.co) in third-quarter pain sales Thursday, even as its expanding ADHD business helped revenue reach a record $216.3 million. Revenue rose 3% from $209.4 million a year earlier, but both reported and adjusted earnings fell, according to the earnings release accompanying its SEC filing.

## Higher Sales, Lower Earnings

Operating expenses reached $96.7 million, a 44% increase from $67.1 million a year earlier. Even after Collegium’s adjustments, expenses rose 25%, to $69.4 million from $55.7 million.

The earnings release put [net income](https://www.sec.gov/Archives/edgar/data/0001267565/000162828026070585/coll-2026x09x30xex99x1.htm?ref=bullished.co) at $21.8 million, compared with $31.5 million a year earlier. Diluted earnings per share dropped from $0.84 to $0.60; adjusted earnings were $1.96 per share on $75.2 million of net income, versus $2.25 and $87.3 million.

Adjusted earnings before interest, taxes, depreciation and amortization fell 9%, to [$121.6 million](https://www.globenewswire.com/news-release/2026/11/05/3396299/0/en/collegium-reports-third-quarter-2026-financial-results-reaffirms-2026-guidance.html?ref=bullished.co) from $133.0 million. COLL shares fell about 3% to $24.40 in Friday trading.

## ADHD Expands, Pain Contracts

Jornay PM delivered [$51.9 million](https://www.globenewswire.com/news-release/2026/11/05/3396299/0/en/collegium-reports-third-quarter-2026-financial-results-reaffirms-2026-guidance.html?ref=bullished.co) in sales, up 24% year-over-year. Prescription volume rose 16%, while its prescriber base grew 19% to nearly 33,000, a record for the medicine.

Vikram Karnani, Collegium’s president and chief executive officer, attributed ADHD demand to “expanded commercial efforts heading into the [back-to-school season](https://www.sec.gov/Archives/edgar/data/0001267565/000162828026070585/coll-2026x09x30xex99x1.htm?ref=bullished.co).” Azstarys added $26.5 million in its first full quarter under Collegium ownership, with prescriptions increasing nearly 2% year-over-year after declining in 2025.

The ADHD expansion rests on acquisitions. The [2024 Ironshore purchase](https://www.sec.gov/Archives/edgar/data/0001267565/000162828026070585/collq32026earningspresen.htm?ref=bullished.co) brought Jornay PM and a sales team focused on neuropsychiatry and pediatrics; Collegium added Azstarys in May 2026, using its existing commercial infrastructure. Chief Financial Officer Colleen Tupper said ADHD now accounts for more than 36% of revenue.

Pain medicines still generated $138.0 million. Belbuca sales slipped 1% to $57.7 million, Xtampza ER fell 9% to $45.8 million, and the Nucynta franchise dropped 44% to $30.8 million. Nucynta’s total included $4.2 million from Hikma Pharmaceuticals USA for authorized generic versions of Nucynta and Nucynta ER.

## Forecasts Hold, Buyback Settlement Ahead

Collegium retained its 2026 revenue outlook of [$825 million](https://www.benzinga.com/news/26/11/62920002/collegium-pharmaceutical-q3-2026-earnings-call-transcript?ref=bullished.co) to $855 million, including $190 million to $200 million for Jornay PM and $65 million to $75 million for Azstarys. Its forecast for adjusted earnings before interest, taxes, depreciation and amortization also stayed at $445 million to $470 million.

Operations generated $86.5 million in cash during the quarter. Collegium ended the period with $144.8 million in cash, cash equivalents and marketable securities.

Capital returns remain part of the plan. Collegium’s earnings presentation describes a [$50 million buyback](https://www.sec.gov/Archives/edgar/data/0001267565/000162828026070585/collq32026earningspresen.htm?ref=bullished.co) announced during the third quarter, structured as an accelerated share repurchase.

Collegium expects final settlement of that previously announced repurchase in the fourth quarter of 2026.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — COLLEGIUM PHARMACEUTICAL, INC (COLL)](https://www.sec.gov/Archives/edgar/data/0001267565/000162828026070585/coll-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit coll-2026x09x30xex99x1.htm — COLLEGIUM PHARMACEUTICAL, INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001267565/000162828026070585/coll-2026x09x30xex99x1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit collq32026earningspresen.htm — COLLEGIUM PHARMACEUTICAL, INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001267565/000162828026070585/collq32026earningspresen.htm?ref=bullished.co) — SEC EDGAR
- [Collegium Pharmaceutical Q3 2026 Earnings Call Transcript](https://www.benzinga.com/news/26/11/62920002/collegium-pharmaceutical-q3-2026-earnings-call-transcript?ref=bullished.co) — benzinga.com
- [Collegium Reports Third Quarter 2026 Financial Results;](https://www.globenewswire.com/news-release/2026/11/05/3396299/0/en/collegium-reports-third-quarter-2026-financial-results-reaffirms-2026-guidance.html?ref=bullished.co) — globenewswire.com

### More on Collegium Pharmaceutical

- [Collegium Pays Grünenthal $17 Million To End Nucynta License And Royalties, Settling Patent Suit](https://www.bullished.co/collegium-pays-grunenthal-17-million-to-end-nucynta-license-and-royalties-settling-patent-33f3364e/)

[All Collegium Pharmaceutical (COLL) coverage →](https://www.bullished.co/tag/coll/)